Harrow to Acquire Melt Pharmaceuticals, Advancing Non-Opioid, Needle-Free Sedation Therapy MELT-300

Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, announced that it has entered into an ag...

September 30, 2025 | Tuesday | News
Philips Unveils Next-Generation CT and Helium-Free MR Systems to Transform Precision and Sustainability in Radiation Therapy

New Rembra RT and Areta RT [1] CT platforms drive accuracy and efficiency in radiation therapy with advanced workflows and long-term value Philips deb...

September 29, 2025 | Monday | News
Sen-Jam and KVK Tech Complete NDA-Ready CMC Package and Submission Batches for SJP-002C

Completion of submission batches and NDA-ready CMC package strengthens regulatory foundation for upcoming Phase 2b/3 trials and underscores Sen-Jam's lea...

September 29, 2025 | Monday | News
European Commission Approves Lilly’s Kisunla™ (donanemab) for Early Symptomatic Alzheimer’s Disease

Approved for use in the earliest symptomatic stages, Kisunla is the only once-monthly amyloid plaque–targeting therapy with evidence supporting tre...

September 26, 2025 | Friday | News
Eisai and Biogen Gain Australian Approval for LEQEMBI® in Early Alzheimer’s Disease

Eisai Co., Ltd. and Biogen Inc. announced that the Therapeutic Goods Administration (TGA) of Australia has approved LEQEMBI® (lecanemab), a humanized...

September 25, 2025 | Thursday | News
Ncardia Launches First iPSC-Derived Non-Human Primate Cardiomyocytes for Translational Cardiac Research

-Ncardia, a leader in stem cell–based solutions for drug discovery and safety assessment,  announced the launch of Ncyte® NHP-C vCardiomyo...

September 24, 2025 | Wednesday | News
Actio Biosciences Doses First Participant in Phase 1a Trial of ABS-1230 for KCNT1-Related Epilepsy

Actio Biosciences, a clinical-stage biotechnology company leveraging a novel approach to genetics and precision medicine to develop new small molecule th...

September 24, 2025 | Wednesday | News
Remedium Bio and Eli Lilly Enter Multi-Target Gene Therapy Collaboration in Type 2 Diabetes and Obesity

Lifespan Vision Ventures is pleased to announce that its portfolio company, Remedium Bio, Inc. ("Remedium"), has entered into a multi-target research and...

September 24, 2025 | Wednesday | News
Rise Therapeutics Expands Oral Dendritic Cell Modulator Program into Sjögren’s Disease Following Positive RA Clinical Data

Supported by recent clinical data from the first-ever clinical study of an oral dendritic cell (DC) modulator in rheumatoid arthritis (RA), Rise Therapeu...

September 24, 2025 | Wednesday | News
Australia’s Immutep and GW Cancer Center Launch Phase II Trial of Efti in Early-Stage HR+/HER2-Negative Breast Cancer

GW Cancer Center to initiate Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in HR+/HER...

September 23, 2025 | Tuesday | News
Esperion and Otsuka Secure MHLW Approval for NEXLETOL® in Japan to Treat Hypercholesterolemia

Esperion announced that Otsuka Pharmaceutical Co., Ltd. (Otsuka), the Company’s partner for the development and commercialization of NEXLETOL® ...

September 22, 2025 | Monday | News
Alvotech and Fuji Pharma Secure Japanese Approval for Three New Biosimilars: Denosumab, Golimumab, and Aflibercept

Alvotech a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced th...

September 22, 2025 | Monday | News
Ipsen Secures MHLW Approval for Bylvay® in Japan to Treat Pruritus in Progressive Familial Intrahepatic Cholestasis (PFIC)

Bylvay® is the first once-daily ileal bile acid transport inhibitor to be approved as a treatment for pruritus associated with progressive familial...

September 22, 2025 | Monday | News
Ono Pharmaceutical and Deciphera Secure European Commission Approval for Vimseltinib (ROMVIMZA™) as First Therapy for TGCT in the EU

Vimseltinib is the first and only therapy with marketing authorization for the treatment of TGCT in the European Union Ono Pharmaceutical Co.,...

September 18, 2025 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close